DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20201905

Prevalence of HER-2/ neu receptor amplification and its effects over prognosis of the patients with breast cancer

Rekha Melwani, Sadaf Jabeen Malik, Sobohi Shakeel, Amna Begum, Sarwat Khalid, Syed Naqeeb Ali

Abstract


Background: The diagnosis and prognosis of patients with breast cancer is routinely carried out with biopsy of growth by H&E staining but it is not commonly practice with various immunomarkers including HER2/neu. However HER2/neu association in breast tumour patients with prognosis has not been studied much, so this study is aim to evaluate the frequency of HER2 (human epidermal growth factor receptor) amplification and its effects over prognosis among the patients with breast cancer.

Methods: After ethical approval, retrospective observational study was conducted from October 2014 to September 2017. All operated patients with biopsy proven breast cancer, the patients having any stage of disease, with sufficient data present in hospital record and patients who received neo-adjuvant chemo-therapy/radio-therapy were included. Patients unfit for surgery due to co-morbidities like cardio renal diseases and patients having insufficient hospital record or who missed follow-ups were excluded. SPSS version 20.0 was used for data analysis for data analysis with qualitative data presented as frequency and percentages.

Results: A Total 120 patients, 48(40%) had HER-2/ neu positive. Among the HER2 +ve patients, 17(35.4%) had local recurrence within 03 years while 21(43.7%) cases had distant recurrence. The disease free survival rate in 03 years was observed in 22(45.83%) out of 48 HER2 +ve cases.

Conclusions: Study reveals 40% patients had HER-2/neu positive expression and was associated with poor outcomes and disease free survival time period in comparison to patient with HER-2/ neu negative.


Keywords


Breast Carcinoma, Human epidermal growth factor receptor, Immunohistochemistry

Full Text:

PDF

References


Soto-Perez-De-Celis E, Loh KP, Baldini C, Battisti NM, Chavarri-Guerra Y, De Glas NA, et al. Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives. Expert Opini Investigat Drugs. 2018 Oct 3;27(10):787-801.

Morgan S, Amemiya Y, Slodkowska E, LU FI, Parra-Herran C, Nofech-Mozes S, et al. Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients. Anticanc Res. 2019 Oct 1;39(10):5345-52.

Kaufmann R, Müller P, Hildenbrand G, Hausmann M, Cremer C. Analysis of Her2/neu membrane protein clusters in different types of breast cancer cells using localization microscopy. J Microsc. 2011;242(1):46-54.

Balluff B, Elsner M, Kowarsch A, Rauser S, Meding S, Schuhmacher C, et al. Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier. J Proteo Res. 2010;9(12):6317-22.

Buza N, Roque DM, Santin AD. HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med. 2014;138(3):343-50.

Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133(3):831-41.

Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clini Oncol. 2010;28(10):1684-91.

Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat. 2011;125(2):553-61.

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, et al. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. Int J Radiat Oncol Biol Phys. 2011;80(4):1095-101.

Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist. 2010;15(11):1164-8.

Mendoza ES, Moreno E, Caguioa PB. Predictors of early distant metastasis in women with breast cancer. J Cancer Res Clini Oncol. 2013;139(4):645-52.

Perry C, Conway CM, Ha JW, Braunschweig T, Morris J, Ylaya K, et al. HER-2 assessment in formalin-fixed paraffin-embedded breast cancer tissue by well-based reverse phase protein array. Clin Proteomics. 2014;11(1):1-8.

Schmidt G, Gerlinger C, Juhasz-Böss I, Stickeler E, Rody A, Liedtke C, et al. Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer. J Cancer Res Clin Oncol. 2016;142(6):1369-1376.

Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, et al. Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist. 2011;16(7):956-65.

Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clini Oncol. 2015;33(31):3660-7.

Callahan R, Hurvitz S. HER2-positive breast cancer: current management of early, advanced, and recurrent disease. Curr Opin Obstetr Gynecol. 2011(1):37-43.

Zubeda S, Kaipa PR, Shaik NA, Mohiuddin MK, Vaidya S, Pavani B, et al. Her-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India. Asian Pac J Cancer Prev. 2013;14(4):2231-5.

Hurvitz SA, Hu Y, O’Brien N, Finn RS. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treatm Rev. 2013;39(3):219-29.

Munzone E, Nolé F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clini Breast Cancer. 2010;10(5):392-7.

Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Nat Cancer Inst. 2007;99(8):628-38.

English DP, Roque DM, Santin AD. HER-2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Molec Diagn Ther. 2013;17(2):85-99.

Montemurro F, Di Cosimo S, Arpino G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol. 2013;24(11):2715-24.

Niwińska A, Tacikowska M, Murawska M. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Inter J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1134-9.

Kamil M, Yusuf N, Khalid I, Islam R, Biswas M, Hashim H. Association between HER-2/neu over-expression and clinico-pathologic parameters of breast cancer in northern Malaysia. Ceyl Medi J. 2010 Mar 30;55(1):1-5.

Kong Y, Dai S, Xie X, Xiao X, Lv N, Guo J, et al. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clini Oncol. 2012;138(2):275-84.

Tagliabue E, Balsari A, Campiglio M, Pupa SM. HER2 as a target for breast cancer therapy. Expert Opin Biolog Ther. 2010;10(5):711-24.

Luoh SW, Ramsey B, Newell AH, Troxell M, Hu Z, Chin K, et al. HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression. Springer Plus. 2013;2(1):386-96.

Boku N. HER-2 positive gastric cancer. Gastric Cancer. 2014;17(1):1-2.

Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, et al. Expression of Her-2 in carcinomas of the esophagus. Am J Surgi Pathol. 2010;34(12):1868-73.

Buza N, Roque DM, Santin AD. HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Medi. 2014;138(3):343-50.

Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clini Oncol. 2013;31(16):1997-2003.